| Neal S. Walker |
Dr. Neal S. Walker is an Independent Director at Aldeyra Therapeutics, Inc., a Chairman, President & Chief Executive Officer at Aclaris Therapeutics, Inc. and a President & Director at Aclaris Life Sciences, Inc. He is on the Board of Directors at Aldeyra Therapeutics, Inc., Active Protective Technologies, Inc., Life Sciences Pennsylvania, Myota, Inc., Ralexar Therapeutics, Inc., Zoomi, Inc. and Aclaris Life Sciences, Inc. Dr. Walker was previously employed as a Co-Founder by NeXeption LLC, a President & Chief Executive Officer by Vicept Therapeutics, Inc., a Chief Medical Officer by Trigenesis Therapeutics, Inc., a Medical Consultant by Astra Merck, Inc., a President by Cutix Pharmaceuticals, Inc., a Co-Founder by Cutix, Inc., an Executive Chairman by Follica, Inc., a Consultant by Genta, Inc., and a Consultant by Johnson & Johnson. He also served on the board at Octagon Research Solutions, Inc., Advancing Innovation in Dermatology, Inc., Dermatology Innovation Forum and Sebacia, Inc. He received his undergraduate degree from Lehigh University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from Philadelphia College of Osteopathic Medicine. |
| Christopher P. Molineaux |
Christopher P. Molineaux is currently the President & Chief Executive Officer at Life Sciences Pennsylvania since 2009. He is also the Lead Independent Director at Aclaris Therapeutics, Inc. since 2014. Additionally, he serves as a Director at Chester County Economic Development Council. In the past, Mr. Molineaux worked as the VP-Pharmaceutical Communication & Public Affairs at Johnson & Johnson from 2002 to 2009. He also held positions as Principal at Blue Cross & Blue Shield Association, Public Affairs Executive at Health & Human Services Agency Data Center, and Public Affairs Executive at the US Department of Health & Human Services (DC). Prior to that, he was the Vice President-Public Affairs at Pharmaceutical Research & Manufacturers Association from 1999 to 2002. Mr. Molineaux completed his undergraduate degree at the College of the Holy Cross (Massachusetts). |
| Joseph B. Monahan |
Joseph B. Monahan is the founder of Aclaris Life Sciences, Inc., which was founded in 2010. He holds the title of Director & Chief Scientific Officer at Aclaris Life Sciences, Inc. Dr. Monahan is currently the Chief Scientific Officer at Aclaris Therapeutics, Inc. Dr. Monahan's former job was at Pfizer Inc., where he held the title of Executive Director-Inflammation Research. Dr. Monahan's education includes an undergraduate degree from the State University of New York at Buffalo and a doctorate degree from the University of South Carolina. |
| James Loerop |
James Loerop currently works at Aclaris Therapeutics, Inc., as Chief Business Officer from 2022. Mr. Loerop also formerly worked at Anika Therapeutics, Inc., as EVP-Business Development & Strategic Planning, Alexion Pharmaceuticals, Inc., as SVP-Global Business Development, Stiefel Laboratories, Inc., as SVP-Global Corporate Development, Lupin Pharmaceuticals, Inc., as Chief Corporate Development Officer, and GlaxoSmithKline LLC, as VP-North America Business Development. Mr. Loerop received his undergraduate degree from Western Michigan University. |
| Kevin Balthaser |
Kevin Balthaser is currently the Chief Financial Officer at Aclaris Therapeutics, Inc. and a Member at The American Institute of Certified Public Accountants. He completed his undergraduate degree at The Pennsylvania State University and earned an MBA from Villanova University in 1990. |
| Ajay Aggarwal |
Ajay Aggarwal is currently working as the Senior Vice President-Clinical Development at Aclaris Therapeutics, Inc. Previously, he worked as the Chief Medical Officer at CereXis, Inc. Dr. Aggarwal holds a doctorate degree from All India Institute of Medical Sciences and an MBA from Kellogg School of Management, which he obtained in 1990. |
| Maxine Gowen |
Maxine Gowen was the founder of Trevena, Inc. (founded in 2007) and held the title of Director from 2018 to 2021. She is currently the Chairman at Passage Bio, Inc. and a Director at Conforma Therapeutics Corp., Aclaris Therapeutics, Inc., Merus NV, and TamuroBio, Inc. She has also held former positions as an Independent Director at Human Genome Sciences, Inc. from 2008 to 2012, an Independent Director at Idera Pharmaceuticals, Inc., a Director at Morphotek, Inc., Santarus, Inc., and Azelon Pharmaceuticals, Inc., and a Director at Biotechnology Innovation Organization from 2008 to 2018. Additionally, she served as a Director at Life Sciences Pennsylvania from 2015 to 2021, an Independent Director at Akebia Therapeutics, Inc. from 2014 to 2021, a Director at Panorama Medicine, Inc. from 2020 to 2021, and an Independent Director at Aceragen, Inc. from 2016 to 2023. Dr. Gowen's education includes a doctorate from the University of Bath, an undergraduate degree from the University of Bristol (conferred in 1979), a doctorate from The University of Sheffield (conferred in 1984), and an MBA from The Wharton School of the University of Pennsylvania (conferred in 2002). |
| Andrew Kenneth William Powell |
Andrew Kenneth William Powell currently works at Aclaris Therapeutics, Inc., as Independent Director from 2017, Cure Network Ventures, Inc., as Director from 2017, SciaDerm, Inc., as Director, and Gibson, Dunn & Crutcher LLP, as Associate. Mr. Powell also formerly worked at Lifecore Biomedical, Inc., as Independent Director from 2020 to 2022, Synthorx, Inc., as Independent Director from 2018 to 2020, Motif Bio Plc, as Non-Executive Director in 2019, Silverback Therapeutics, Inc., as Independent Director from 2020 to 2022, Baxter International, Inc., as Vice President & Chief International Counsel, ImClone LLC, as Senior Vice President & General Counsel from 2008 to 2009, CollaGenex Pharmaceuticals, Inc., as Secretary, Executive VP & General Counsel from 2004 to 2008, InterMune, Inc., as Secretary, Executive VP & General Counsel from 2013 to 2015, Medivation LLC (California), as Secretary, Senior Vice President & General Counsel from 2015 to 2016, and Cornerstone Therapeutics, Inc., as Secretary, Executive VP & General Counsel from 2009 to 2013. Mr. Powell received his undergraduate degree in 1979 from The University of North Carolina at Chapel Hill and graduate degree in 1985 from Stanford Law School. |
| Vincent J. Milano |
Vincent J. Milano is currently the Chairman of Life Science Cares Philadelphia. He is also an Independent Director at BioCryst Pharmaceuticals, Inc., a Director at Biotechnology Innovation Organization, and an Independent Director at Aclaris Therapeutics, Inc. Mr. Milano previously served as the President, Chief Executive Officer & Director of Idera Pharmaceuticals, Inc. from 2014 to 2022. He was also the Chairman, President & Chief Executive Officer of Shire ViroPharma, Inc. from 2008 to 2014. Additionally, he held the position of Chairman-Elect at Life Sciences Pennsylvania from 2011 to 2012. Mr. Milano was the Chairman of Aceragen, Inc. and a Director at BravoSolution US, Inc. from 2003 to 2008. He served as an Independent Director at Vanda Pharmaceuticals, Inc. from 2010 to 2019 and as a Director at Venatorx Pharmaceuticals, Inc. from 2013 to 2022. He was also an Independent Director at Spark Therapeutics, Inc. from 2014 to 2019. Prior to his roles in the pharmaceutical industry, Mr. Milano worked as a Senior Manager at KPMG LLP from 1985 to 1996. Mr. Milano obtained his undergraduate degree from Rider University. |
| William D. Humphries |
William D. Humphries is currently the Chief Executive Officer & Director at Onpharma, Inc. He is also the Chief Executive Officer at Alcami Corp., Inc. and Isosceles Pharmaceuticals, Inc. Additionally, he serves as the Chairman-Global Luxury Management Board at North Carolina State University and as the Chairman at Merz LLC. Furthermore, he holds positions as an Independent Director at PhaseBio Pharmaceuticals, Inc., STRATA Skin Sciences, Inc., Aclaris Therapeutics, Inc., Clearside Biomedical, Inc., and Bryn Pharma LLC. In his former roles, Mr. Humphries served as the Chairman, President & Chief Executive Officer at Merz, Inc. and Merz North America, Inc. He was also the Group Chairman & Executive Vice President at OraPharma, Inc. and the Chairman at Merz Pharmaceuticals LLC. Additionally, he held positions as the President & Director at Medicis Pharmaceutical Corp., Director at ZARS Pharma, Inc., Ulthera, Inc., American Skin Association, Inc., and Merz Aesthetics, Inc. He also served as a Director at Merz Pharma Canada Ltd. and as the Vice President-US Skin Care at Allergan, Inc. from 1996 to 2004. From 2009 to 2012, he was the President-Dermatology at Stiefel Laboratories, Inc. and from 2018 to 2020, he served as the President-Ortho Dermatologics at Bausch Health Cos., Inc.Mr. Humphries completed his undergraduate degree at Bucknell University in 1988. He also holds an MBA from Pepperdine University, which he obtained in 1998. |
| Bryan Marlen Reasons |
Bryan Marlen Reasons is currently the Chairman at Impax Laboratories (Taiwan), Inc. He is also an Independent Director at Aclaris Therapeutics, Inc., the President & Director at Mallinckrodt Hospital Products, Inc., a Director at MKG Medical UK Ltd., the Executive VP, Chief Financial & Accounting Officer at Mallinckrodt Plc, and the Chief Financial Officer & Executive Vice President at Mallinckrodt Pharmaceuticals Ltd. In his former positions, Mr. Reasons served as an Independent Director at Societal CDMO, Inc. from 2017 to 2024. He was the Vice President-Finance at Cephalon, Inc. from 2005 to 2011 and at Teva Pharmaceutical Industries Ltd. from 2011 to 2012. From 2012 to 2018, he held the position of Chief Financial Officer & Senior VP-Finance at Impax Laboratories LLC. Prior to that, he worked as a Senior Manager at PricewaterhouseCoopers LLP from 1992 to 2003 and as the Vice President-Finance at DuPont de Nemours, Inc. from 2003 to 2005. He also served as the Chief Financial Officer & Senior Vice President at Amneal Intermediate, Inc. and Amneal Pharmaceuticals, Inc. from 2018 to 2019. Mr. Reasons obtained his undergraduate degree from The Pennsylvania State University. He also holds an MBA from Widener University, which he received in 1992. |
| Anand Mehra |
Anand Mehra is currently the Chairman at Merus NV since 2020. He is also an Independent Director at Aclaris Therapeutics, Inc. and a Director at First Aid Beverages, Inc., Amplyx Pharmaceuticals, Inc., and Sofinnova Management VIII LLC. Previously, Dr. Mehra served as an Independent Director at Marinus Pharmaceuticals, Inc. from 2007 to 2016. He was also a Director at Aerie Pharmaceuticals, Inc., NextWave Pharmaceuticals, Inc., Vicept Therapeutics, Inc., Civitas, and Amarin Pharma, Inc. Additionally, he held the position of Independent Director at Spark Therapeutics, Inc. from 2014 to 2019. Dr. Mehra was the Managing General Partner & Principal at Sofinnova Investments, Inc. from 2007 to 2020. He also worked as a Principal at McKinsey & Co., Inc., an Associate at Panorama Capital LLC, and a Principal at JPMorgan Private Capital Asia Corp.Dr. Mehra completed his undergraduate studies at the University of Virginia and obtained a doctorate degree from Columbia University College of Physicians & Surgeons. CURRENT JOB: Chairman at Merus NV. |
| Andrew N. Schiff |
Andrew N. Schiff is currently the Chairman at Visiting Nurse Service of New York. He is also the Non-Executive Chairman at Monte Rosa Therapeutics, Inc. since 2023. In addition, he serves as an Independent Director at Aclaris Therapeutics, Inc. and as a Director at Planet Biopharmaceuticals, Inc., Henry Street Settlement, Inc., Planet Technologies, Inc., Dren Bio, Inc., and Aisling Capital LLC, where he has been the Managing Partner since 2000. Previously, Dr. Schiff held positions as a Director at Bioenvision, Inc., Gilead Colorado, Inc., Barrier Therapeutics, Inc., CardioKine, Inc., and SkinMedica, Inc. He was also an Independent Director at Agile Therapeutics, Inc. from 2014 to 2016. Additionally, he served as a Director at ArgiNOx Pharmaceuticals, Inc., PowerVision, Inc., Adams Respiratory Therapeutics, Inc., Sirion Holdings, Inc., Dynova Laboratories, Inc., Colorescience Corp., ZELTIQ Aesthetics, Inc., TransEnterix, Inc., Miramar Technologies, Inc., ARMGO Pharma, Inc., Cempra, Inc., Quintiles Transnational Holdings, Inc., Sirion Therapeutics, Inc., F2G Ltd., Zavante Therapeutics, Inc., Harmony Biosciences Holdings, Inc., and IQVIA RDS Asia, Inc.Dr. Schiff's education includes an undergraduate degree from Brown University, an MBA from The Trustees of Columbia University in The City of New York, and a doctorate from Weill Cornell Medical College. |
